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INTRODUCTION
Chronic non-cancer pain (CNCP), defined 
as a painful condition lasting ≥3 months 
and not associated with a cancer diagnosis, 
is believed to affect 35% to 51% of adults in 
the UK.1 Opioid prescribing to treat CNCP 
has rapidly increased in the last 20 years,2–8 
despite a lack of evidence for the long-term 
safety and effectiveness of these drugs.9–12
Long-term opioid use is associated 
with significant healthcare, workplace, 
and criminal justice costs,13–15 and serious 
adverse events including opioid dependence 
and opioid-related deaths.16–19 
Further, the risk of harm increases at 
high doses, and further benefit is unlikely 
above an average daily morphine equivalent 
dose of 120 mg.20 However, people with 
prescription opioid dependency may not 
access traditional substance misuse clinics 
because they do not perceive themselves to 
be dependent.21 
Public Health England recommends that 
commissioners seek to provide separate 
treatment and support for patients dependent 
on prescription opioids.22 However, evidence 
for the effectiveness of interventions for 
reduced prescribing or opioid cessation in 
people with CNCP is scarce.23 
The South Gloucestershire pain review 
service was designed to investigate the 
feasibility of implementing a service in 
primary care for patients with CNCP 
treated with long-term opioid painkillers. 
The novel service aimed to promote 
appropriate pain management; improve 
health, wellbeing, and quality of life (QoL); 
improve patients’ understanding of opioid 
painkiller dependence and related harms; 
and help patients explore their use of 
opioids, supporting dose reduction where 
appropriate. 
The aim of this study was to evaluate 
the pain review service in terms of health 
and wellbeing outcomes, opioid use, and 
potential impact, and to help inform future 
service provision. Details of the service 
acceptability are presented elsewhere.24
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Abstract
Background
Opioid prescribing to treat chronic non-cancer 
pain has rapidly increased, despite a lack of 
evidence for long-term safety and effectiveness. 
A pain review service was developed to work with 
patients taking opioids long-term to explore opioid 
use, encourage non-drug-based alternatives, and, 
where appropriate, support dose reduction. 
Aim
To evaluate the service and its potential impact on 
opioid use, health and wellbeing outcomes, and 
quality of life (QoL). 
Design and setting
Mixed-methods evaluation of a one-to-one 
service based in two GP practices in South 
Gloucestershire, England, which took place from 
September 2016 to December 2017.
Method
Quantitative data were collected on baseline 
demographics; data on opioid use, misuse, 
and dose, health, wellbeing, QoL, and pain and 
interference with life measures were collected 
at baseline and follow-up. Twenty-five semi-
structured interviews (n = 18 service users, 
n = 7  service providers) explored experiences 
of the service including perceived impacts and 
benefits.
Results
Of 59 patients who were invited, 34 (57.6%) 
enrolled in the service. The median prescribed 
opioid dose reduced from 90 mg (average daily 
morphine equivalent; interquartile range [IQR] 
60 to 240) at baseline to 72 mg (IQR 30 to 160) 
at follow-up (P<0.001); three service users 
stopped using opioids altogether. On average, 
service users showed improvement on most 
health, wellbeing, and QoL outcomes. Perceived 
benefits were related to wellbeing, for example, 
improved confidence and self-esteem, use of pain 
management strategies, changes in medication 
use, and reductions in dose.
Conclusion
The service was well received, and health and 
wellbeing outcomes suggest a potential benefit. 
Following further service development, a 
randomised controlled trial to test this type of care 
pathway is warranted. 
Keywords
chronic non-cancer pain; health promotion; 
opioids; pain; primary health care. 
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METHOD
Recruitment to the pain review service
The service was delivered by two project 
workers across two GP practices in South 
Gloucestershire. Patients eligible for 
inclusion had received ≥3 opioid painkiller 
prescriptions in a 3-month period, had 
taken opioids for ≥3 months (long-term 
opioid use), and were not using illicit drugs 
or receiving end-of-life care. GPs identified 
patients for the service using the opioid risk 
assessment tool (ORAT). Where possible, 
GPs discussed service participation with 
patients directly, before referring them to 
the project worker who posted an invitation 
letter and information sheet. Patients 
who responded were invited to attend an 
information session. Those who attended 
and were interested in continuing in the 
service were enrolled. 
Pain review service 
The South Gloucestershire Council 
Public Health and Wellbeing Division 
commissioned the service for 2 years 
from September 2016. Project workers 
performed a comprehensive and holistic 
assessment of service users, exploring the 
medical and psychosocial factors involved in 
their opioid use. An individually tailored pain 
management plan was developed including 
setting daily goals, developing a relaxation 
plan, introducing gentle exercise, dealing 
with low mood, and improving sleep. In 
addition, access to alternative care and 
support options were available, including 
physiotherapy and relaxation groups. Type 
of opioid drug and dose were reviewed, and 
support with reduction in dose was provided 
if appropriate. The service was delivered 
on a one-to-one basis; the number and 
frequency of sessions were determined 
by service user needs and within project 
workers’ availability. Further details of the 
service can be found in the authors’ linked 
article by Kesten et al.24
Data collection
Quantitative. Anonymised case report 
forms were created to collect quantitative 
data. Data on response to invitation, 
attendance at the information session, 
and enrolment were recorded for all 
invited patients. Baseline demographic 
data, employment, relationship status, 
disabilities, and previous use of a pain 
clinic service were recorded for enrolled 
service users. Baseline opioid drug, overall 
duration, reason for original prescription, 
and motivation for use were documented, 
along with other baseline medications. 
Scores for the following were recorded 
at baseline and follow-up: opioid dose 
(measured as average daily morphine 
equivalent);25 current opioid misuse measure 
(COMM)26 (COMM; scored 0–68 with scores 
≥9 considered positive for misuse); brief 
pain inventory (BPI)27,28 (BPI; severity 
scored 0–40, interference scored 0–70, and 
percentage pain relief from medications 
scored 0–100); Warwick–Edinburgh mental 
wellbeing scale29 (scored 0–70 with a change 
of 3–8 points considered ‘meaningful’); 
and treatment outcomes profile (TOP)30 
(TOP; all scored 0–20) for physical health, 
psychological health, and QoL.
Numbers and reasons for discharge 
and drop-out from service; number of 
How this fits in
Long-term use (≥3 months) of prescription 
opioid painkillers in patients with chronic 
non-cancer pain is associated with opioid 
dependence, addiction, and opioid-related 
deaths. National guidance recommends 
that commissioners provide separate 
services, preferably in primary care, for 
patients who have become dependent on 
prescription opioid painkillers. The South 
Gloucestershire pain review service is a 
novel, primary care-based service aimed at 
helping patients with chronic non-cancer 
pain using long-term opioid painkillers, 
to explore their use of opioids, support 
non-pharmacological pain management 
strategies, and reduce their opioid dosage 
where appropriate. The service was well 
received and showed promising results 
including potential improvements in 
wellbeing, quality of life outcomes, and a 
reduction in opioid dosage.
Approached
n = 59
Contact successful
n = 42
Enrolled
n = 34
Attended information session
n = 41
Contact unsuccessful
(n = 17)
Did not attend information
session (n = 1)
Did not wish to enrol (n = 7): 
Happy with dose (n = 3)
Happy to reduce with GP (n = 1)
‘                     ’ (n = 1)
Client died (n = 1)
No reason given (n = 1)
Not for me
Figure 1. Patient flowchart. 
British Journal of General Practice, Online First 2019  2
appointments made, kept, cancelled, and 
not attended; and duration of follow-up 
were also recorded. 
Data were collected for all patients 
invited to use the service between 
September 2016 (service commencement) 
and December 2017. Data regarding visits 
and treatments were collected up until 
February 2018 for enrolled service users. 
There was no set follow-up time-point for 
this study; follow- up data were collected 
from the final visit within the study period 
where possible, or the closest visit to this 
if final-visit data were missing. All data 
were self-reported except opioid and other 
medication use, which were extracted from 
the GP electronic record system (EMIS) by 
the project workers.
Qualitative. Project workers facilitated 
recruitment of 18 service users for semi-
structured interview by asking those willing 
to take part to complete a ‘consent to 
contact’ form. The second author then 
posted these service users an information 
sheet explaining the study and inviting them 
to contact them if they wished to participate. 
Interviews were also conducted with the 
service providers: project workers (n = 2), 
the project workers’ manager (n = 1), and 
GPs in participating GP practices (n = 4); 
the second author approached these 
participants directly.
Interviews were conducted face-
to-face or by telephone depending on 
interviewee preference. Written or verbal 
informed consent was obtained before 
every interview. Service user interviews 
explored experiences of the service, and 
service provider interviews explored the 
partnership between GPs and project 
workers. Service acceptability was also 
discussed in all interviews; results are 
presented elsewhere.24
Sample
Over the proposed 2-year recruitment 
period, 30–40 service users across two GP 
practices were expected to be invited to 
take part. This was a pragmatic sample 
given the funding, time, and capacity of 
the project workers. All service users 
who enrolled between September 2016 
and December 2017 were included in the 
quantitative analysis, and a convenience 
sample provided qualitative interview data. 
Analysis
Quantitative data were summarised using 
means and standard deviations (SD), medians 
and interquartile ranges (IQR), or counts 
and percentages as appropriate. As data 
were not normally distributed, the Wilcoxon 
signed-rank test was used to assess changes 
between baseline and follow-up opioid 
dose. Due to the small sample size, and 
consequent limited power, other outcomes 
were not formally statistically compared. All 
quantitative data management and analysis 
was carried out using Stata 15.1.
Qualitative interviews were 
audiorecorded, transcribed verbatim, 
anonymised, and analysed thematically.31 
Table 1. Baseline characteristics, medications, and presenting 
issuesa
  Enrolled service users
Characteristics  n/N %b
Female sex  22/34 64.7
Age, years, mean (SD) 51 10
White ethnicity   31/31 100.0
Employment statusc 
 Employed 6/31 19.4 
 Unemployed 23/31 74.2 
 Retired 2/31 6.5
Relationship statusc 
 Single 6/31 19.4 
 Married 19/31 61.3 
 Separated 3/31 9.7 
 Divorced 1/31 3.2 
 Other 2/31 6.5
Disability 20/27 74.1
Previous pain clinic usec 22/31 71.0
Baseline medications, excluding opioids 
 Benzodiazepines 12/34 35.3 
 Amitriptyline 12/34 35.3 
 SSRI antidepressants 8/34 23.5 
 Gabapentin 7/34 20.6 
 Other antidepressants 6/34 17.6 
 Pregabalin 4/34 11.8 
 SNRI antidepressants 1/34 2.9 
 Zopiclone 1/34 2.9
Psychological comorbiditiesc 
 Sleep issues    17/30 56.7 
 Depression    13/29d 44.8 
 Anxiety/panic attacks   9/29e 31.0  
 Experience of child abuse  9/30 30.0  
 Social isolation  7/29 24.1 
 Experience of domestic abuse  5/29 17.2 
 Substance misuse   3/29f 10.3 
 Low mood  3/29 10.3 
 Alcohol misuse   2/29f 6.9 
 Other mental health issues   2/29f 6.9 
 Eating disorder 1/29 3.4 
 Post-traumatic stress disorder 1/29 3.4 
 Self-harm 1/29 3.4 
 Negative self-talk/thoughts 1/29 3.4
aAll details are self-reported except baseline medications. bUnless otherwise stated. cDenominators reflect the total 
number of service users for whom these data were collected. Therefore, denominators of less than 34 indicate 
missing data. dTwelve diagnosed. eSix diagnosed. fAll diagnosed. SNRI = serotonin and norepinephrine reuptake 
inhibitors. SSRI = selective serotonin reuptake inhibitors. 
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NVivo 10 (QSR International) was used to 
aid data management.
Quantitative and qualitative data were 
analysed independently by two researchers 
and integrated using the ‘following a thread’ 
technique32 (a method of integration at the 
analysis stage) through discussion of the 
key findings and themes in both datasets. 
RESULTS
Recruitment, attendance, and retention
Between September 2016 and December 
2017, 59 patients were invited to take part in 
the service. Of these, 42 patients responded 
to the invitation, 41 attended an information 
session, and 34 (57.6% ) enrolled, (Figure 1). 
The enrolled service users had a mean 
age of 51 years (SD 10) and 65% were 
female (Table 1). Many service users were 
also taking other medication at baseline: 
12/34 (35.3%) were taking benzodiazepines; 
12/34 (35.3%) amitriptyline; 8/34 (23.5%) 
SSRI antidepressants, and 7/34 (20.6%) 
gabapentin, (Table 1). Back pain was 
the most common reported reason for 
original opioid prescription (9/32, 28.1%; 
Table 2). Eighteen of the service users were 
interviewed (see Supplementary Table 1 for 
details of these participant characteristics).
Seven service providers were also 
interviewed, including two project workers, 
the project workers’ manager, and four GPs 
in participating GP practices.  
Reasons for non-participation were 
only recorded for the seven patients who 
attended an information session and chose 
not to enrol (Figure 1). The most common 
reason was that they were happy with their 
opioid dose and did not perceive a problem 
(3/7; 42.9%). Data from the service user 
interviews provided possible other reasons 
for non-response. For example, one 
participant was hesitant to enrol because 
of a negative previous experience of pain 
clinics, and another stated an uncertainty 
about the potential benefits of the service. 
Across all enrolled service users, 535 
appointments were made; 390 were kept 
(72.9%), 101 were cancelled (18.9%), and 
44 were not attended (8.2%). During the 
interviews, service users reported missing 
appointments because of ‘bad pain days’ 
and conflicting appointments. 
In patients still using the service when 
data collection finished (n = 17; 50%), 
the median duration of service use was 
7.7 months (IQR 3.2 to 13.3) and the median 
number of attended appointments was 
12 (IQR 6 to 20); in patients who were 
discharged/lost to follow-up (n = 17; 50%), 
the median duration was 3.8 months 
(IQR 1.1 to 9.1), and the median number of 
attended appointments was 6 (IQR 1 to 11). 
Reasons for discharge from service: 
no longer taking opioids (3/17; 17.6%); 
reduction in opioid dose (4/17; 23.6%); 
happy as is (2/17; 11.8%); no time (1/17; 
5.8%); and fears that reduced pain may lead 
to reduced disability benefits affected one 
patient (1/17, 5.8%); and six patients were 
lost to follow-up, that is, stopped returning 
calls from the project worker (6/17, 35.3%). 
Project worker 1 described the service 
duration as varying for each service user, 
with shorter expected duration for service 
users who were either keen to reduce their 
use of opioids or achieve a specific goal, or 
who did not engage with the service within 
the first couple of sessions. 
Awareness and understanding of pain
Several service users described having a 
greater understanding of pain, the function 
of opioids, and their effectiveness for 
chronic pain treatment; this was echoed 
by the GPs. Service users described 
Table 2. Baseline opioid usea
  Enrolled service users
Opioid use n/N %b
Reported reason for original opioid prescriptionc 
 Back pain 9/32 28.1 
 Arthritis 5/32 15.6 
 Spinal or disc degeneration/deformities 5/32 15.6 
 Fibromyalgia 4/32 12.5 
 Other 9/32 28.1
Opioid dose, mg, median (IQR) 90 60 to 240
Opioid drug 
 Codeine 17/34 50.0 
 Tramadol 10/34 29.4 
 Morphine 9/34 26.5 
 Oxycodone family 7/34 20.6 
 Fentanyl 5/34 14.7 
 Buprenorphine 3/34 8.8 
 Methadone 1/34 2.9 
 Multiple opioid drugs  16/34 47.1 
Duration of use, yearsc 
 0–2  2/29 6.9 
 3–4  3/29 10.3 
 5–9 9/29 31.0 
 10–14  6/29 20.7 
 ≥15 9/29 31.0
Motivation for usec 
 Pain 32/32 100.0 
 Coping with feelings 4/32 12.5 
 Addiction/dependence 3/32 9.4 
 Sleep 1/32 3.1 
 Withdrawal allowance 1/32 3.1)
aAll details are self-reported except for opioid drugs. bUnless stated otherwise. cDenominators reflect the total 
number of service users for whom these data were collected. Therefore, denominators of less than 34 indicate 
missing data. IQR = interquartile range. 
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increased awareness of the relationship 
between thought processes, emotions, and 
experiences of pain. 
By tracking patterns in pain and opioid 
use, one project worker and a small number 
of service users noticed that opioids were 
not always taken in response to pain levels, 
as illustrated by the following quote: 
‘… I assumed I was taking it when I needed 
for pain but having a couple of […] pain 
charts and things like that I realised I was 
actually taking it on quite a regular type 
of — yes and I didn’t realise that at all.’ 
(Participant [P] 8, service user [SU])
Service users were able to consider 
approaches to modify their opioid use after 
becoming aware of how they managed their 
pain.
Opioid use and pain management
Of the service users, 82.8% (24/29) had been 
taking prescription opioids for ≥5 years, 
with 31.0% (9/29) taking opioids for at least 
15 years, (Table 2). 
The median prescribed opioid dose 
reduced from 90 mg (IQR 60 to 240) at 
baseline to 72 mg (IQR 30 to 160) at follow-
up (P<0.001; Figure 2); 15 service users 
reduced their dose (44.1%), (3 [8.8%] 
reduced to zero), 19 stayed on the same 
dose (55.9%), and none increased. Of 
service users prescribed >120 mg per day 
at baseline, 4/14 (28.6%) had dropped to 
below 120 mg by follow-up. 
Using the COMM scale, 24/28 (85.7%) 
service users were ‘misusing’ opioids 
(scores ≥9) at baseline compared with 15/22 
(68.2%) at follow-up. 
In support of this, one GP felt that overuse 
of medication among service users had 
reduced, as demonstrated by the following:
 
‘So the people requesting their medication, 
“I’ve lost my prescription”, is always an 
interesting one. “I’m going on holiday”, “My 
Grandma is ill, I need to go to Devon, can 
I have my prescription early?” The various 
excuses that patients use seems to have 
reduced and withered away.’ (P19, GP)
In addition to reduced dose, the interviews 
highlighted several ways in which service 
users had modified their opioid use, such 
as, changing medication type and form, for 
example, pain patches, using paracetamol 
before opioids, not using opioids for ‘break 
out’ pain, using medication less frequently, 
and spreading the dose out over the day. 
The following quote came from a service 
user who found that the service enabled 
them to take their opioids less often and 
slowly reduce the dose:
‘In the beginning I was clock watching. I was 
getting to say quarter to the hour and I was 
thinking, oh quarter of an hour I can take 
some more tablets […] The [service gave] 
me the confidence to just nudge it a little 
bit further apart between taking them and 
then dropping the dose down […] so it was a 
controlled reduction.’ (P1, SU)
Most service users described changing 
their pain management approach and 
how they responded to pain. The following 
techniques were mentioned during 
Figure 2. Prescribed opioid dose at baseline 
and follow-up. P-value for change <0.001. 
IQR = interquartile range. Opioid dose measured as 
average daily morphine equivalent.
Figure 3. Wellbeing and QoL outcomes at baseline 
and follow-up (higher = better). PI = brief pain 
inventory. IQR = interquartile range. QoL = quality 
of life. TOP = treatment outcome profile. Warwick–
Edinburgh = Warwick–Edinburgh mental wellbeing 
scale.
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service user interviews: using ‘pacing’ 
(breaking up tasks into manageable parts), 
using relaxation exercises to manage 
pain, persevering with activities when pain 
was bad, increasing physical activity, for 
example, by walking or dancing, and trying 
to improve their diet. 
A small number of service users reported 
increased pain levels and withdrawal 
side effects, for example, sweating and 
headaches, as a result of reducing opioids. 
These experiences corresponded to the 
quantitative data showing a small reduction 
in median BPI percentage pain relief from 
medications between baseline (60, IQR 30 
to 70) and follow-up (50, IQR 30 to 70) 
(Figure 3).
These data all illustrate that by using the 
service it is possible for service users to 
develop new pain management techniques, 
which may enable them to take opioids less 
often and/or reduce their dose.
Health, wellbeing, and quality of life
Service users had, on average, improved on 
most health, wellbeing, and QoL outcome 
scales (Figures 3 and 4). For example, 
14/22 (63.6%) improved by ≥3 points and 
9/22 (40.9%) improved by ≥8 points on the 
Warwick–Edinburgh mental wellbeing 
scale.
Interviews captured several factors that 
contributed to improving QoL including 
self-kindness, starting new hobbies, 
volunteering, cooking more often, and 
greater involvement in looking after 
grandchildren. These activities had positive 
effects on wellbeing, feelings of self-worth, 
and distraction from pain symptoms. A 
small number of service users described 
having a greater support network and 
one GP described a service user as less 
sedated and more able to interact socially. 
Several service users also described sleep 
improvements. In contrast, no service users 
reported a reduction in QoL. The following 
quote illustrates a GP’s experience of the 
change in their patient’s awareness:
‘The patient I had from this morning has 
gone from coming in in a wheelchair to 
walking in herself […] Her speech was 
always quite slurred. She’d fall asleep in 
consultations. Really quite sedated. Her 
degree of alertness is completely different 
today […] I think the knock-on effect then for 
her is she’s going to fall less. She’s got more 
interaction. You know socially she’s able to 
do more.’ (P19, GP)
Several service users described small 
positive effects on their mental health, 
including acceptance of long-term pain, a 
more positive attitude towards managing 
their pain and in general, and feeling 
better in themselves. Service users, project 
workers, and a GP described service users 
experiencing increased confidence, self-
esteem, motivation to manage their pain, 
capacity to try new things, and ability to 
communicate their needs more assertively. 
The following quote illustrates a service 
user’s improved attitude:
‘I feel happier. More positive really, trying to 
do more things, see more people.’ (P12, SU)
It was also recognised that these changes 
take time and several service users noted 
that their relationship with pain had not 
changed. These data demonstrate that 
the service has the potential to improve 
wellbeing and QoL. However, it is not clear 
what aspects of the service may have 
contributed to these improvements.
Healthcare use and delivery
GPs described fewer consultations with 
‘high demand’ service users. Similarly, a 
few service users described reductions 
in GP consultations and one commented 
that not being admitted to hospital during 
service participation was a positive 
outcome. Despite this, the lead GPs did 
not feel the service saved them time as 
they were involved in identifying eligible 
patients and meeting project workers for 
service user reviews. GPs also described 
greater consideration of prescribing 
appropriateness and reflected that they 
had more confidence when explaining the 
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Figure 4. Wellbeing and QoL outcomes at baseline 
and follow-up (lower = better). COMM = current 
opioid misuse measure. BPI = brief pain inventory. 
QoL = quality of life.
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effectiveness of opioids for chronic pain 
management.
DISCUSSION
Summary
On average, most health, wellbeing, and 
QoL outcomes improved and many service 
users also reported improved QoL during 
interviews. In addition, 15/34 (44.1%) of 
service users had reduced their opioid dose, 
three of whom had stopped taking opioids 
completely, and interview data suggested 
service users had a better understanding of 
their pain and pain management. 
Strengths and limitations
The main strength of this study was the use 
of mixed methods to evaluate the service 
and to understand the potential impact of 
the intervention on the target group.33,34 
Factors to consider for future service 
development are discussed in the authors’ 
linked article by Kesten et al.24
There are four main limitations. First, the 
sample size was small, and quantitative 
follow-up data were not available for 
some service users (particularly those 
who dropped out early). This not only 
meant that formally assessing health and 
wellbeing outcomes was not possible, 
but also highlighted the need for further 
consideration about follow-up data 
collection in future studies. In particular, 
defining a set follow-up time point for 
evaluation and collecting data from all 
service users at that time, regardless of 
drop-out, would be important. 
Second, because of the service users’ 
close relationship with the project workers,24 
they may have been reluctant to provide 
negative outcomes relating to the service 
during interviews. However, the findings 
reflect a range of positive and negative 
experiences suggesting that service users 
felt free to express negative experiences. 
Third, the data around other medication 
use, psychological comorbidities, and 
motivations for opioid use were self-
reported, and as such some service users 
may have omitted details they did not wish 
to share. 
Finally, economic data were not collected 
so the impact of the intervention on GP 
resources could not be formally assessed 
as part of this study. These issues would 
all need to be addressed in a future larger 
randomised controlled trial (RCT) or study to 
formally test the effectiveness of the service.
Comparison with existing literature
The UK Faculty of Pain Medicine 
recommends that a collaborative treatment 
plan between patient and doctor should be 
developed to address long-term prescription 
opioid use.35,36 They also recommend a 
flexible approach, either involving a single 
clinician or a multidisciplinary team with 
clear communication and documentation, 
and that the role of peer support should 
also be considered.37 
A recent systematic review examined 
primary care-based models for medication-
assisted treatment (MAT) for opioid use 
disorder (OUD).38 MAT combines behavioural 
therapy and counselling with medications 
such as methadone, buprenorphine, and 
naltrexone. 
The authors found that successful 
programmes used multidisciplinary 
models, integrating clinical teams with 
other support staff. However, only three 
studies were based in the UK, and the 
included studies primarily focused on illicit 
opioids, not prescription opioid painkillers. 
In terms of RCTs, a brief, 3-day, 
group-based pain management support 
intervention for chronic musculoskeletal 
pain (COPERS) was not effective in reducing 
pain-related disability at 12 months, though 
benefits were observed for depression 
and social integration;39 these results are 
similar to those found in the presented 
study. 
The I-WOTCH trial is currently underway 
examining the effectiveness of a group 
multicomponent self-management 
intervention combined with individual 
support for people using strong opioids for 
chronic non-cancer pain;40,41 results from 
this study will be important in adding to the 
evidence regarding an individually tailored 
approach. 
Implications for research and practice
In the absence of non-opioid/non-drug-
based interventions, it should come as no 
surprise that healthcare professionals are 
prescribing opioids and that patients are 
self-medicating in an attempt to address 
complex conditions. There is a need to focus 
on improving GP prescribing behaviour so 
that patients are only started on opioids 
when appropriate.42 Where the decision is 
made to prescribe opioids, patients should 
be monitored and reviewed more regularly 
so that opioids are stopped when they are 
no longer providing any benefit and there 
is early identification of problems such as 
dependence.43 
More research is needed to identify 
effective primary care-based interventions 
targeting: primary prevention of opioid 
painkiller dependence in patients with 
chronic non-cancer pain, that is, better 
Funding
This article summarises independent 
research funded by the National Institute 
for Health Research Collaboration for 
Leadership in Applied Health Research 
and Care West (NIHR CLAHRC West) 
at University Hospitals Bristol NHS 
Foundation Trust and a postdoctoral 
fellowship award held by Kyla Thomas 
(grant reference: PDF-2017-10-068). The 
views expressed are those of the author(s) 
and not necessarily those of the NHS, the 
NIHR, or the Department of Health and 
Social Care. Joanna Kesten is partly funded 
by NIHR CLAHRC West and the NIHR 
Health Protection Research Unit (HPRU) in 
Evaluation of Interventions. Sabi Redwood 
and Lauren Scott’s time is supported by the 
NIHR CLAHRC West at University Hospitals 
Bristol NHS Foundation Trust. Matthew 
Hickman’s time is supported by the NIHR 
HPRU in Evaluation of Interventions. Rona 
Campbell’s time is supported by the Centre 
for the Development and Evaluation of 
Complex Interventions for Public Health 
Improvement (DECIPHer), a UKCRC Public 
Health Research Centre of Excellence. 
The authors gratefully acknowledge joint 
funding from the British Heart Foundation 
(reference number: MR/KO232331/1), 
Cancer Research UK, Economic and Social 
Research Council, Medical Research 
Council, the Welsh Government, and the 
Wellcome Trust, under the auspices of the 
UK Clinical Research Collaboration.
7  British Journal of General Practice, Online First 2019
pain management, appropriate opioid 
prescribing, education about opioid-related 
benefits and harms, use of prescribing 
systems, medication reviews, and non-
drug-based interventions to address the 
pain; secondary prevention, that is, early 
recognition and intervention; and tertiary 
prevention, that is, pharmacological and 
non-pharmacological measures. 
The present findings suggest that it is 
possible for patients with chronic non-
cancer pain on long-term opioids to be 
managed in a primary care setting. Service 
users improved their understanding of pain 
and pain management, and more than 40% 
of service users also reduced their opioid 
dosage. Additionally, GPs reported more 
informed opioid prescribing with greater 
consideration of the appropriateness of 
opioid prescribing, as well as increased 
confidence in explaining the benefits and 
harms for this patient cohort. Though the 
results of the study are promising, further 
development of the service is required,24 
followed by a more robust evaluation of the 
intervention, ideally an RCT.
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